NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd
Post# of 122
(Total Views: 150)
Posted On: 12/12/2022 3:25:36 PM
NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Regains Compliance with Nasdaq Listing Rules
BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced the receipt of formal notifications from the Nasdaq Stock Market that the company has regained Nasdaq compliance regarding minimum stockholders’ equity and minimum bid price. The company previously reported receipt of the respective non-compliance notifications on Sept. 30 and Nov. 2, 2022. According to the update, Nasdaq indicated that it has determined, based on BiondVax’s Form 6-K dated Nov. 30, 2022, reporting third-quarter financial results, that the company once again complies with Listing Rule 5550(b)(1) regarding minimum $2.5 million stockholders’ equity. In addition, Nasdaq confirmed that since the minimum bid price has now closed over $1.00 per share for the past ten trading days, the company once again complies with Listing Rule 5550(a)(2).
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced the receipt of formal notifications from the Nasdaq Stock Market that the company has regained Nasdaq compliance regarding minimum stockholders’ equity and minimum bid price. The company previously reported receipt of the respective non-compliance notifications on Sept. 30 and Nov. 2, 2022. According to the update, Nasdaq indicated that it has determined, based on BiondVax’s Form 6-K dated Nov. 30, 2022, reporting third-quarter financial results, that the company once again complies with Listing Rule 5550(b)(1) regarding minimum $2.5 million stockholders’ equity. In addition, Nasdaq confirmed that since the minimum bid price has now closed over $1.00 per share for the past ten trading days, the company once again complies with Listing Rule 5550(a)(2).
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)BiondVax Pharmaceuticals Ltd. (BVXV) Stock Research Links
Scroll down for more posts ▼